Primary Biliary Cholangitis Market
Jun 11, 2024
Moderna’s Phase III Trials for Dual Influenza and COVID-19 Vaccine; Almirall’s Klisyri FDA Approval; Lilly’s Tirzepatide MASH Trial; Cycle Pharmaceuticals Acquisition of Vanda Pharmaceuticals; Ipsen’s Iqirvo FDA Approval
Moderna Reports Successful Phase III Trials for Dual Influenza and COVID-19 Vaccine Moderna, Inc. has reported that its Phase III trial for mRNA-1083, an experimental combination vaccine targeting both influenza and COVID-19, achieved its main objectives by generating a stronger immune response than the approved...
Read More...
Feb 13, 2023
PPAR and NOX Agonist: Savior of Underserved Primary Biliary Cholangitis Patients
Primary biliary cholangitis (PBC), earlier known as primary biliary cirrhosis, is an autoimmune disorder that leads to the gradual destruction of intrahepatic bile ducts resulting in periportal inflammation cholestasis. Prolonged hepatic cholestasis subsequently leads to cirrhosis and portal hypertension. As per...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
